Patents by Inventor Christopher John Burns

Christopher John Burns has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20080194583
    Abstract: Compounds of general formula (I), (II) (III) and (V) are described for use in modulating microtubule polymerisation and in the treatment of associated disease states. Use of compounds (I), (III) and (V) in the treatment of kinase-associated disease states is also described. Further described are novel compounds of formula (II), (III) and (V).
    Type: Application
    Filed: December 3, 2004
    Publication date: August 14, 2008
    Inventors: Christopher John Burns, Andrew Frederick Wilks, Michael Francis Harte, Harrison Sikanyika, Emmanuelle Fantino, Collette Gloria Kewdale
  • Patent number: 7259179
    Abstract: A compound of the general formula: or pharmaceutically acceptable salts, hydrates, solvates, crystal forms or diastereomers thereof is described. A method of treating protein kinase-associated disease states using the compound of formula I is also described.
    Type: Grant
    Filed: May 23, 2003
    Date of Patent: August 21, 2007
    Assignee: Cytopia Research Pty Ltd
    Inventors: Christopher John Burns, Xianyong Bu, Andrew Frederick Wilks
  • Patent number: 7122550
    Abstract: A compound of the general formula: or pharmaceutically acceptable salts, hydrates, solvates, crystal forms of diastereomers thereof is described. A method of treating protein kinase-associated disease states using the compound of Formula I is also described.
    Type: Grant
    Filed: May 23, 2003
    Date of Patent: October 17, 2006
    Assignee: Cytopia Pty Ltd
    Inventors: Christopher John Burns, Xianyong Bu, Andrew Frederick Wilks
  • Publication number: 20040235862
    Abstract: A compound of the general formula: 1
    Type: Application
    Filed: December 4, 2003
    Publication date: November 25, 2004
    Inventors: Christopher John Burns, Xianyong Bu, Andrew Frederick Wilks
  • Publication number: 20040102455
    Abstract: The present invention provides methods of inhibiting JAK involving the use of a group of compounds based either upon a 2-amino-6-carba-disubstituted pyrazine scaffold or a 2-amino-6-carba-disubstituted pyridine scaffold. The invention also provides methods of treating JAK-associated disease states.
    Type: Application
    Filed: July 30, 2003
    Publication date: May 27, 2004
    Inventors: Christopher John Burns, Andrew Frederick Wilks
  • Patent number: 6417009
    Abstract: A linker lipid for use in attaching a membrane including a plurality of ionophores to an electrode and providing a space between the membrane and the electrode in which the membrane is either in part or totally made up of the linker lipid. The linker lipid has within the same molecule a hydrophobic region capable of spanning the membrane, an attachment group used to attach the molecule to an electrode surface, a hydrophilic region intermediate the hydrophobic region and the attachment group, and a polar head group region attached to the hydrophobic region at a site remote from the hydrophilic region. The attachment group has a cross sectional area greater than the cross sectional area of the hydrophilic region, and has the structure recited in the specification.
    Type: Grant
    Filed: March 8, 1999
    Date of Patent: July 9, 2002
    Assignees: Australian Membrane and Biotechnology Institute, The University of Sydney
    Inventors: Burkhard Raguse, Christopher John Burns, Leslie David Field, Damon Donald Ridley
  • Patent number: 6380396
    Abstract: The present invention provides intermediates for the preparation of compounds of the formula wherein R, R1, W, X, Y, Ar and ZA are defined herein.
    Type: Grant
    Filed: December 11, 2000
    Date of Patent: April 30, 2002
    Assignee: Pfizer Inc.
    Inventors: Sandra Marina Monaghan, David Alker, Christopher John Burns
  • Patent number: 6207678
    Abstract: The present invention provides a compound of formula (I) wherein R is phenyl, C3-C7 cycloalkyl or heteroaryl, each of which being optionally benzo- or C3-C7 cycloalkyl-fused and optionally substituted, including in the benzo- or C3-C7 cycloalkyl-fused portion, by from 1 to 3 substituents each independently selected from C1-C4 alkyl, fluoro(C1-C4)alkyl, C1-C4 alkoxy, fluoro(C1-C4)alkoxy, phenoxy, C2-C4 alkanoyl, halo, C1-C4 alkoxycarbonyl, C3-C7 cycloalkyl, —S(O)m(C1-C4 alkyl), cyano, —NR2R3, —S(O)mNR2R3, —NR4(C1-C4 alkanoyl) and —CONR2R3, or R is 2,3-dihydrobenzo[b]furanyl or chromanyl; R1 is H or C1-C6 alkyl; W is a direct link, methylene or ethylene; X is unbranched C2-C4 alkylene; Y is phenyl, naphthyl, benzyl, pyridyl, thienyl or C3-C7 cycloalkyl, each of which being optionally substituted by from 1 to 3 substituents each independently selected from C1-C4 alkyl, fluoro(C1-C4)alkyl, C1-C4 alkoxy, fluoro(C1-C4)alkoxy, halo and cyano; Ar is phenyl, naphthyl, benzyl, th
    Type: Grant
    Filed: April 24, 2000
    Date of Patent: March 27, 2001
    Assignee: Pfizer INC
    Inventors: Sandra Marina Monaghan, David Alker, Christopher John Burns